In Other Journals

Tanya Grassi
Med J Aust 2008; 188 (4): . || doi: 10.5694/j.1326-5377.2008.tb01602.x
Published online: 18 February 2008

A novel tetravalent meningococcal vaccine appears to be safe and effective in infants, according to the results of a British and Canadian randomised controlled trial. The meningococcal vaccine currently used in the United States to immunise adolescents (serogroup ACWY) is poorly immunogenic in infants — the group with the highest rates of disease. The researchers administered the tetravalent conjugated meningococcal vaccine (MenACWY) to 225 UK and 196 Canadian infants and compared results with a monovalent vaccine. Outcome measures were safety, reactogenicity and human complement serum bactericidal activity — a measure of vaccine effectiveness. MenACWY was well tolerated and immunogenic for the tested serogroups. A booster at 12 months was found to address the problem of waning titres by this age. Despite limitations associated with the small size of the study, the authors conclude the new vaccine extends immune protection in infants and appears to be safe.

  • Tanya Grassi



remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.